KUALA LUMPUR: Solution Group Bhd has entered into a supply agreement with the Health Ministry to supply Convidicea, a recombinant novel coronavirus vaccine also known as adenovirus type 5 vaccine.
In a statement, Solution said its wholly-owned subsidiary Solution Biologics Sdn Bhd (SOLBIO) would supply 3.5 million doses of the vaccine to MOH.
The vaccine was jointly developed by CanSino Biologics Inc and Beijing Institute of Biotechnology, Academy of Military Medical Sciences.
CanSino has also authorised SOLBIO and granted it the exclusive right to register, manufacture and commercialise the vaccine in Malaysia.
“SOLBIO is in the process of setting up a state-of-the-art fill and finish (F&F) facility to produce the vaccine in Malaysia. We will also be the regional F&F hub for CanSino to supply the vaccine to Singapore, Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos, and Brunei,” Solution Group CEO Datuk Dr. Mohd Nazlee Kamal said.
The company has received approval from the National Pharmaceutical Regulatory Agency (NPRA) for the F&F facility design plan and layout in December 2020.
“We expect our 20,000 sq ft F&F hub located at Technology Park Malaysia to be operational by the second quarter of 2021 and to produce up to three million vials of vaccines per month”.